HRTT logo

Heart Tronics, Inc. (HRTT) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

$'dan işlem gören Heart Tronics, Inc. (HRTT), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 48/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 16 Mar 2026
48/100 AI Puanı

Heart Tronics, Inc. (HRTT) Sağlık ve Boru Hattı Genel Bakışı

CEOBudimir S. Drakulic
Çalışanlar13
MerkezStudio City, US
Halka Arz Yılı1999
SektörHealthcare

Heart Tronics, Inc. is a medical device company specializing in the research, development, and marketing of devices for physiological signal monitoring in the United States. Their product portfolio includes the Fidelity 100 Monitor System and several devices in development, positioning them in the competitive medical devices market.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 16 Mar 2026

Yatırım Tezi

Heart Tronics, Inc. operates in the medical device sector, focusing on cardiac monitoring solutions. The company's potential lies in the successful development and commercialization of its pipeline products, such as the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System. However, the company faces challenges common to small medical device companies, including regulatory hurdles, competition, and the need for significant capital investment to bring products to market. With a market capitalization of $0.00B and a negative P/E ratio, the company's financial performance and future prospects are highly dependent on its ability to secure funding and achieve regulatory approvals. The negative beta of -2.08 suggests an inverse correlation with the market, which could be a factor for investors to consider.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Heart Tronics, Inc. operates in the medical device industry, focusing on cardiac monitoring solutions.
  • The company's flagship product is the Fidelity 100 Monitor System, an integrated ECG signal monitoring system.
  • Several products are in the development stage, including the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System.
  • The company has a market capitalization of $0.00B.
  • Heart Tronics has a negative P/E ratio, reflecting its current financial performance.

Rakipler & Benzerleri

Güçlü Yönler

  • Proprietary technology in physiological signal acquisition.
  • Integrated system approach with the Fidelity 100 Monitor System.
  • Pipeline of products in development targeting various cardiac monitoring needs.
  • Long-standing presence in the medical device industry.

Zayıflıklar

  • Limited financial resources and market capitalization.
  • Dependence on successful development and commercialization of pipeline products.
  • Competition from larger, more established medical device companies.
  • OTC market listing indicates higher risk and lower liquidity.

Katalizörler

  • Upcoming: Regulatory approval and commercial launch of the Fidelity 350 Holter Monitor.
  • Upcoming: Strategic partnerships with medical device distributors and healthcare providers.
  • Upcoming: Integration of Heart Tronics' devices with telehealth platforms.
  • Ongoing: Continued research and development of new medical devices.
  • Ongoing: Expansion of the Fidelity 200 Event Recording System/Heart Tempo Card into the consumer market.

Riskler

  • Potential: Failure to secure regulatory approvals for pipeline products.
  • Potential: Competition from larger, more established medical device companies.
  • Potential: Limited financial resources and difficulty in raising capital.
  • Ongoing: Technological obsolescence and the emergence of competing technologies.
  • Ongoing: Dependence on successful commercialization of a limited number of products.

Büyüme Fırsatları

  • Successful Commercialization of Fidelity 350 Holter Monitor: The Fidelity 350 Holter Monitor, designed for ambulatory ECG data collection, represents a significant growth opportunity. The market for Holter monitors is driven by the increasing need for arrhythmia detection and transient heart disease monitoring outside of clinical settings. If Heart Tronics can secure regulatory approval and effectively market this device, it could capture a share of the ambulatory cardiac monitoring market, estimated to reach several billion dollars globally. Timeline for commercialization depends on regulatory approvals, potentially within the next 2-3 years.
  • Expansion of Fidelity 200 Event Recording System/Heart Tempo Card: The Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device, offers a direct-to-consumer approach to cardiac monitoring. This product targets individuals seeking early detection and personal monitoring of their heart condition. The market for consumer-based health monitoring devices is expanding rapidly, driven by increasing health awareness and technological advancements. Successful market penetration could lead to significant revenue growth. Market size is projected to reach over $20 billion by 2028.
  • Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with established medical device distributors and healthcare providers can significantly expand Heart Tronics' market reach. Collaborations can facilitate access to new markets and customer segments, accelerating product adoption and revenue growth. These partnerships can also provide valuable resources and expertise in areas such as regulatory compliance and marketing. Timeline for establishing partnerships is ongoing, with potential deals emerging within the next 1-2 years.
  • Development and Launch of Fidelity 400 Intracardiac Monitor: The Fidelity 400 Intracardiac Monitor, which applies proprietary physiological signal acquisition technology to read intracardiac signals, represents a potential breakthrough in cardiac monitoring. This device could offer improved accuracy and insights into intracardiac activity, addressing a critical need in cardiology. Successful development and commercialization could position Heart Tronics as a leader in intracardiac monitoring technology. However, this is a longer-term project, with potential launch in 3-5 years.
  • Expansion into Telehealth and Remote Patient Monitoring: Integrating Heart Tronics' devices with telehealth platforms and remote patient monitoring systems can create new revenue streams and enhance patient care. The telehealth market is experiencing rapid growth, driven by increasing demand for remote healthcare services and technological advancements. By offering integrated solutions, Heart Tronics can capitalize on this trend and expand its market presence. The timeline for integration with telehealth platforms is ongoing, with potential for significant progress in the next 2 years.

Fırsatlar

  • Expanding market for cardiac monitoring devices due to increasing prevalence of heart disease.
  • Growing demand for remote patient monitoring and telehealth solutions.
  • Potential for strategic partnerships and distribution agreements.
  • Advancements in wireless technology and data analytics for improved monitoring capabilities.

Tehditler

  • Stringent regulatory requirements and approval processes.
  • Technological obsolescence and the emergence of competing technologies.
  • Economic downturns and reduced healthcare spending.
  • Product liability and safety concerns.

Rekabet Avantajları

  • Proprietary Physiological Signal Acquisition Technology: Heart Tronics possesses unique technology for acquiring and amplifying physiological signals, potentially providing a competitive edge in signal clarity and accuracy.
  • Integrated System Approach: The Fidelity 100 Monitor System offers an integrated solution for ECG monitoring, combining hardware and software for comprehensive data collection and analysis.
  • Pipeline of Development Products: The company has several products in the development stage, offering the potential for future revenue streams and market expansion.
  • Established Brand Name: Heart Tronics, formerly Signalife, has been in operation since 1987, establishing a brand presence and reputation within the medical device industry.

HRTT Hakkında

Heart Tronics, Inc., formerly known as Signalife, Inc., was incorporated in 1987 and rebranded in November 2008. Headquartered in Studio City, California, the company focuses on the research, development, and marketing of medical devices designed to monitor and measure physiological signals. These devices aim to aid in the early detection and management of diseases affecting individual health. The company's flagship product, the Fidelity 100 Monitor System, is an integrated system that collects, processes, and amplifies electrocardiogram (ECG) signals via a set of electrodes wirelessly transmitting data to a laptop. Heart Tronics also has several products in the development stage, including the Fidelity 350 Holter Monitor, an ambulatory device for detecting arrhythmia and transient heart disease, and the Fidelity 200 Event Recording System/Heart Tempo Card, a non-prescription heart monitoring device. Additional products include the Cardiac Vest and the Fidelity 400 Intracardiac Monitor, which applies proprietary signal acquisition technology to read intracardiac signals. Heart Tronics aims to provide innovative solutions for cardiac monitoring and diagnostics.

Ne Yaparlar

  • Researches and develops medical devices.
  • Markets medical devices in the United States.
  • Focuses on devices that monitor and measure physiological signals.
  • Offers the Fidelity 100 Monitor System for ECG signal monitoring.
  • Develops ambulatory Holter monitors for arrhythmia and heart disease detection.
  • Creates non-prescription heart monitoring devices for early detection.

İş Modeli

  • Develops and sells medical devices for cardiac monitoring.
  • Generates revenue through the sale of the Fidelity 100 Monitor System.
  • Aims to generate future revenue from the sale of devices currently in development.
  • Potentially generates revenue through partnerships and distribution agreements.

Sektör Bağlamı

Heart Tronics, Inc. operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory requirements. The market for cardiac monitoring devices is driven by the increasing prevalence of cardiovascular diseases and the growing demand for early and accurate diagnostics. Competition is intense, with established players and emerging companies vying for market share. Heart Tronics' success depends on its ability to differentiate its products, navigate regulatory pathways, and secure funding for research and development. The industry is also influenced by technological advancements, such as wireless connectivity and remote monitoring, which are shaping the future of cardiac care.

Kilit Müşteriler

  • Hospitals and clinics that use cardiac monitoring devices.
  • Physicians who need tools for diagnosing and monitoring heart conditions.
  • Patients who require ECG monitoring and cardiac health assessments.
  • Individuals seeking non-prescription heart monitoring devices for early detection.
AI Güveni: 79% Güncellendi: 16 Mar 2026

Finansallar

Grafik & Bilgi

Heart Tronics, Inc. (HRTT) hisse senedi fiyatı: Price data unavailable

Son Haberler

HRTT için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

HRTT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

HRTT için Wall Street fiyat hedefi analizi.

MoonshotScore

48/100

Bu puan ne anlama geliyor?

MoonshotScore, HRTT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Budimir S. Drakulic

CEO

Budimir S. Drakulic serves as the CEO of Heart Tronics, Inc. His background includes experience in managing small teams and overseeing the operations of the company. Information regarding his specific educational background and previous roles is not available. As CEO, he is responsible for the overall strategic direction and management of Heart Tronics, including research and development, marketing, and financial performance. He manages a team of 13 employees.

Sicil: Under Budimir S. Drakulic's leadership, Heart Tronics has focused on the development and marketing of its medical devices, including the Fidelity 100 Monitor System. Key milestones include the continued development of the Fidelity 350 Holter Monitor and Fidelity 200 Event Recording System. The company's progress is contingent on securing regulatory approvals and achieving commercial success with its product pipeline. Specific financial achievements and strategic decisions are not detailed in the provided information.

HRTT OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Heart Tronics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQB or OTCQX. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in increased risk and potential for fraud or manipulation.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: As an OTC Other stock, Heart Tronics, Inc. likely experiences low trading volume and wide bid-ask spreads. This can make it difficult for investors to buy or sell shares at desired prices, potentially leading to significant price fluctuations and increased transaction costs. The limited liquidity can also make it challenging to establish a fair market value for the stock.
OTC Risk Faktörleri:
  • Limited or no financial disclosure, making it difficult to assess the company's financial health.
  • Low trading volume and wide bid-ask spreads, leading to potential price volatility.
  • Higher risk of fraud or manipulation due to less stringent regulatory oversight.
  • Potential for delisting or suspension of trading due to non-compliance with OTC market requirements.
  • Limited access to capital and funding opportunities compared to companies listed on major exchanges.
Durum Tespiti Kontrol Listesi:
  • Verify the company's legal status and registration with relevant authorities.
  • Attempt to obtain and review any available financial statements or disclosures.
  • Assess the company's management team and their experience in the medical device industry.
  • Research the company's products and their potential market demand.
  • Evaluate the company's competitive landscape and its ability to differentiate itself.
  • Understand the risks associated with investing in OTC Other stocks.
  • Consult with a financial advisor before making any investment decisions.
Meşruiyet Sinyalleri:
  • Company has been in operation since 1987, indicating a long-standing presence in the industry.
  • Focus on research and development of medical devices, suggesting a commitment to innovation.
  • Development of the Fidelity 100 Monitor System and other products, demonstrating tangible progress.
  • CEO Budimir S. Drakulic is managing 13 employees, suggesting a functional organizational structure.
  • Company is headquartered in Studio City, California, a known business hub.

HRTT Healthcare Hisse Senedi SSS

HRTT için değerlendirilmesi gereken temel faktörler nelerdir?

Heart Tronics, Inc. (HRTT) şu anda yapay zeka skoru 48/100, düşük puanı gösteriyor. Temel güçlü yan: Proprietary technology in physiological signal acquisition.. İzlenmesi gereken birincil risk: Potential: Failure to secure regulatory approvals for pipeline products.. Bu bir finansal tavsiye değildir.

HRTT MoonshotScore'u nedir?

HRTT şu anda MoonshotScore'da 48/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

HRTT verileri ne sıklıkla güncellenir?

HRTT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler HRTT hakkında ne diyor?

HRTT için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

HRTT'a yatırım yapmanın riskleri nelerdir?

HRTT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Failure to secure regulatory approvals for pipeline products.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

HRTT'ın P/E oranı nedir?

HRTT için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için HRTT'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

HRTT aşırı değerli mi, yoksa düşük değerli mi?

Heart Tronics, Inc. (HRTT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

HRTT'ın temettü verimi nedir?

Heart Tronics, Inc. (HRTT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Information is limited to the provided source data.
  • AI analysis is pending and may provide additional insights.
  • OTC market stocks carry higher risk than exchange-listed stocks.
Veri Kaynakları

Popüler Hisseler